drugset / Trial / NCT00835276
Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 180 mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd. with that of 180 mg ALLEGRA® Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 180 mg tablet) in healthy adult volunteers under fasting conditions.
Timeline
- Start
- 2002-03
- Primary completion
- 2002-03
- Completion
- 2002-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fexofenadine | Unknown | 180 mg | Oral |
Indications
No indication recorded.